
Second Cancer Risk Declines in Modern-Era Hodgkin Lymphoma Survivors
Key Takeaways
- National cohort follow-up (median 20.2 years) identified 1467 invasive subsequent malignancies in 1200 women, with cumulative SPM incidence reaching 35.6% at 50 years for pre-1990 treatment.
- Radiotherapy use declined markedly (98% pre-1980 to 47% in 2000–2010), and lower supradiaphragmatic dose correlated dose-dependently with reduced breast and lung cancer risk.
Modern Hodgkin lymphoma treatment is tied to a 25% drop in solid second cancers, but breast and lung cancer risks persist for decades.
Women treated for Hodgkin lymphoma (HL) in more recent decades experienced a 25% reduction in subsequent solid cancer risk compared with women treated before 1990, largely reflecting reduced radiotherapy use and exposure, according to findings from a national cohort study published November 12, 2026, in the Journal of Clinical Oncology.¹ However, risks of breast and lung cancers remained elevated more than 40 years after treatment, highlighting the importance of long-term survivorship monitoring.
The population-based study evaluated 7428 women diagnosed with HL before age 36 years in England and Wales between 1954 and 2010. Investigators assessed subsequent primary malignancies (SPMs) and examined how treatment-related factors influenced long-term cancer risk.
During a median follow-up of 20.2 years, 1200 women developed 1467 invasive cancers. The standardized incidence ratio (SIR) for all subsequent invasive malignancies was 3.3 (95% CI, 3.1-3.5), indicating that cancer incidence was more than 3 times higher than expected in the general population. Breast, lung, and thyroid cancers were the most frequently observed malignancies.
Reduced Radiotherapy Exposure Is Associated With Lower Cancer Risk in Hodgkin Lymphoma
HL treatment approaches have evolved considerably, with smaller radiation fields, lower radiation doses, and chemotherapy regimens that reduce reliance on traditional alkylating agents.
These changes were reflected in the study population. Radiotherapy use decreased from 98% among women treated before 1980 to 47% among those treated between 2000 and 2010. Mean supradiaphragmatic radiation dose also declined from 38 Gy to 33 Gy.
Meanwhile, chemotherapy use increased from 55% to 97%, accompanied by a shift away from classic alkylating agents and toward anthracycline-based regimens.
Investigators observed a dose-dependent association between supradiaphragmatic radiotherapy exposure and the risk of several solid malignancies, including breast and lung cancers (P for trend < .001 for both).
Compared with chemotherapy alone, radiotherapy alone was associated with a higher risk of subsequent cancers (HR, 1.87; P < .001), as was the combination of chemotherapy and radiotherapy (HR, 1.96; P < .001). The greatest relative risk of breast cancer was observed among women receiving radiotherapy alone (HR, 3.33; P < .001), whereas the highest lung cancer risk occurred among those receiving combined chemotherapy and radiotherapy (HR, 4.72; P = .031).
Additional analyses demonstrated differences in associations between chemotherapy and individual cancer types. Among women receiving radiotherapy, alkylating agent use was associated with a lower risk of breast cancer (HR, 0.77; P = .01), but a higher risk of gastrointestinal cancers when alkylators were administered without anthracyclines (HR, 2.20; P = .006).
After adjustment for radiotherapy use and dose, the reduction in solid cancer risk across treatment eras was attenuated. However, adjustment for chemotherapy use did not substantially change the trend, suggesting that reduced radiation exposure was the primary contributor to improvements in long-term solid cancer risk.
Breast and Lung Cancer Risks Persist Decades After Treatment
Despite improvements associated with modern treatment approaches, subsequent malignancies remained a substantial concern for HL survivors.
The cumulative incidence of SPMs reached 35.6% at 50 years of follow-up among women treated before 1990. Women who received radiotherapy, either alone or with chemotherapy, also experienced approximately twice the cumulative incidence of subsequent cancers at 40 years compared with those treated with chemotherapy alone.
Breast cancer was the most frequently observed subsequent malignancy, accounting for 648 cases, or approximately 44% of all SPMs. Lung cancer represented another major contributor, with 122 cases. Both cancer types remained important sources of excess risk among survivors.
Importantly, solid malignancy risks remained significantly elevated beyond 40 years after treatment. The benefits of more recent treatment approaches became more apparent after 10 years of follow-up, consistent with the latency period associated with radiation-related malignancies.
Younger age at initial HL treatment was also associated with higher subsequent solid cancer risk. In contrast to the reduction observed in solid malignancies, investigators found no decline in hematologic malignancy risk across treatment eras.
Findings Reinforce Need for Long-Term Survivorship Monitoring in Hodgkin Lymphoma
The findings support continued risk-based screening and follow-up for women previously treated for HL, particularly those who received radiation involving breast tissue at younger ages.
In the United Kingdom, women who received supradiaphragmatic irradiation are offered annual breast cancer screening beginning 8 years after treatment.2 A UK pilot study also demonstrated the feasibility of low-dose computed tomography screening among HL survivors, supporting further research into targeted lung cancer screening strategies.3
Aislinn Macklin-Doherty, MD, of The Royal Marsden, and investigators emphasized that subsequent cancer risks remain clinically relevant long after successful HL treatment, underscoring the need for “vigilant screening in high-risk subgroups who receive irradiation, particularly at young ages.”¹
The investigators acknowledged limitations, including the inability to precisely determine radiation exposure to individual organs and the lack of detailed chemotherapy dose information. Additionally, the study did not evaluate the long-term effects of newer systemic therapies, including immunotherapies and antibody-drug conjugates, on subsequent malignancy risk.
Overall, the findings suggest that changes in HL treatment have reduced the long-term burden of subsequent solid cancers, particularly through decreased radiotherapy exposure. Nevertheless, persistent breast and lung cancer risks reinforce the importance of individualized, long-term surveillance for survivors.
REFERENCES
1. Macklin-Doherty A, Cunningham D, Chau I, et al. Second cancer risk in female survivors of Hodgkin lymphoma: a national cohort analysis across treatment eras. J Clin Oncol. Published online November 12, 2026. doi:10.1200/JCO-26-00418.
2. Breast screening: very high risk women surveillance protocols. NHS England. Updated November 11, 2026. Accessed November 20, 2026. https://www.gov.uk/government/publications/breast-screening-higher-risk-women-surveillance-protocols
3. Broadbent R, Crosbie P, Armitage CJ, et al. Pilot study of lung cancer screening for survivors of Hodgkin lymphoma. Haematologica. 2024;109(10):3305-3313. doi:10.3324/haematol.2023.283287
Related to this article








